| Previous Close | 2.9000 |
| Open | 3.1300 |
| Bid | 0.0000 x 1200 |
| Ask | 0.0000 x 1300 |
| Day's Range | 2.9000 - 3.1300 |
| 52 Week Range | 2.6660 - 30.2400 |
| Volume | 70,257 |
| Avg. Volume | 196,121 |
| Market Cap | 5.269M |
| Beta (5Y Monthly) | -1.06 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Akers Biosciences, Inc. (the “Company”) (AKER), a developer of rapid health information technologies, today announced that it reached a settlement agreement to settle two shareholder derivative actions: Watts v. Gormally, et al., No. 2:18-15992 (D.N.J.) and Chan v. Gormally, et al., No. 2:19-cv-4989 (D.N.J.). As previously reported, on October 2, 2019, the plaintiffs filed a motion for preliminary approval of the settlement. On January 8, 2020, the court entered an order that, among other things, granted preliminary approval of the settlement, approved the form and content of the parties' proposed notice of the settlement, directed the Company to issue a press release containing the information in that notice by today, and scheduled a hearing on May 28, 2020 to consider final approval of the settlement.
Akers Biosciences, Inc. (the “Company”) (AKER), a developer of rapid health information technologies, announced today that on December 10, 2019, it received notice from the Hearings Advisor of the Nasdaq Office of General Counsel that the Company successfully regained compliance with the minimum bid price requirements set forth under Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market and that the Company is in compliance with all other applicable listing standards.
THOROFARE, NJ / ACCESSWIRE / December 10, 2019 / Akers Biosciences, Inc. (NASDAQ:AKER), will be presenting at this year's Investor Summit on December 17 th in Philadelphia. The Investor Summit will take ...
Akers Biosciences, Inc. (the “Company” or “we”) (AKER), a developer of rapid health information technologies, today announced the closing of its previously announced public offering of 613,500 common units at a public offering price of $4.00 per unit and 1,376,500 pre-funded units at a public offering price of $3.9999 per pre-funded unit, raising gross proceeds of $7.96 million, before deducting placement agent’s fees and other estimated offering expenses payable by Akers, assuming none of the preferred stock warrants issued in this offering are exercised. H.C. Wainwright & Co. is acted as exclusive placement agent for the offering. Each unit sold in this offering is comprised of one share of common stock and one preferred stock warrant to purchase one share of Series C Convertible Preferred Stock.
Akers Biosciences, Inc. (the “Company”) (AKER), a developer of rapid health information technologies, today announced that Executive Chairman Christopher Schreiber will attend the “Hemp Industry Daily Forum” on Tuesday, December 10, 2019 as part of MJBizCon Week at the Las Vegas Convention Center in Las Vegas, Nevada. Akers Advisory Board member Bob Hoban is a featured speaker presenting on “International Opportunities” for Hemp operations within the Textiles to Cannabidiol (CBD) space.
Akers Biosciences, Inc. (the “Company” or “we”) (AKER), a developer of rapid health information technologies, today announced the pricing of a public offering of 1,990,000 units. Each unit is comprised of one share of common stock (or common stock equivalent) and one preferred stock warrant to purchase one share of Series C Convertible Preferred Stock. The units are being offered at a public offering price of $4.00 per unit.
Akers Biosciences, Inc. (the “Company” or “we”) (AKER), a developer of rapid health information technologies, today announced that it will continue its strategic review and has identified the hemp and minor cannabinoid sectors as promising adjacent opportunities that could benefit from Akers’ core competencies. The company is exploring how to leverage its 30 years of operational history in its medical device business, where its current products have U.S. Food and Drug Administration (FDA) clearance, its current operations practice Good Manufacturing Processes (cGMP), its medical device facility is certified under ISO 13485 – 2016 and the facility carries an Analytical Lab Certification for Schedules 2, 3, 4 and 5 controlled substances issued by the U.S. Drug Enforcement Administration (DEA) and the State of New Jersey.
THOROFARE, N.J., Nov. 22, 2019 -- Akers Biosciences, Inc. (NASDAQ: AKER), (“Akers Bio” or the "Company"), a developer of rapid health information technologies, today announced.
NEW YORK, Sept. 25, 2019 -- The Rosen Law Firm, P.A. announces that the hearing to determine whether to approve a proposed class action settlement that would benefit purchasers.
Akers Biosciences, Inc. (AKER) (“Akers Bio” or the “Company”), a developer of rapid health information technologies, reported its financial results for the three and six months ended June 30, 2019. At June 30, 2019, Akers Bio had cash, restricted cash and marketable securities of $4.39 million. The Board of Directors’ process remains underway to evaluate strategic alternatives to maximize shareholder value.
NEWARK, N.J., July 29, 2019 -- The Rosen Law Firm, P.A. announces that the United States District Court District of New Jersey has approved the following announcement of a.
Akers Biosciences, Inc. (AKER) (“Akers Bio” or the “Company”), a developer of rapid health information technologies, reported its financial results for the three months ended March 31, 2019. At March 31, 2019, Akers Bio had cash, restricted cash and marketable securities of $5.23 million. During the fourth quarter of 2018, the Board of Directors initiated a process to evaluate strategic alternatives to maximize shareholder value.
Akers Biosciences, Inc. (AKER) (“Akers Bio” or the “Company”), a developer of rapid health information technologies, reported its financial results for the fiscal year ended December 31, 2018. At December 31, 2018, Akers Bio had cash, restricted cash and marketable securities of $5.96 million, which the Company reports is sufficient to fund its obligations into 2020. The process is ongoing and will consider a range of potential strategic alternatives including, but not limited to, business combinations in alternative sectors including cannabis related industries.